Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetic Patients by Kim, Sung-Tae et al.
D I A B E T E S  &  M E T A B O L I S M   J O U R N A L
This is an Open Access article distributed under the terms of the Creative Commons At-
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Copyright © 2011 Korean Diabetes Association  http://e-dmj.org
Diabetes Metab J 2011;35:41-49
Basal C-peptide Level as a Surrogate Marker of 
Subclinical Atherosclerosis in Type 2 Diabetic Patients
Sung-Tae Kim
1, Byung-Joon Kim
1,2, Dong-Mee Lim
1,2, In-Geol Song
1, Jang-Han Jung
1, Kang-Woo Lee
1,2, 
Keun-Young Park
1,2, Youn-Zoo Cho
1, Dae-Ho Lee
3, Gwan-Pyo Koh
3
1Department of Internal Medicine, Konyang University Hospital, Konyang University School of Medicine, Daejon,
2Konyang University Myunggok Medical Research Institute, Daejon,
3Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea
Background:  Recent studies have revealed that C-peptide induces smooth muscle cell proliferation and causes human athero-
sclerotic lesions in diabetic patients. The present study was designed to examine whether the basal C-peptide levels correlate with 
cardiovascular risk in type 2 diabetes mellitus (T2DM) patients. 
Methods:  Data was obtained from 467 patients with T2DM from two institutions who were followed for four years. The medi-
cal findings of all patients were reviewed, and patients with creatinine >1.4 mg/dL, any inflammation or infection, hepatitis, or 
type 1 DM were excluded. The relationships between basal C-peptide and other clinical values were statistically analyzed. 
Results:  A simple correlation was found between basal C-peptide and components of metabolic syndrome (MS). Statistically 
basal C-peptide levels were significantly higher than the three different MS criteria used in the present study, the Adult Treat-
ment Panel III (ATP III) of the National Cholesterol Education Program’s (NCEP’s), World Health Organization (WHO), and 
the International Diabetes Federation (IDF) criteria (NCEP-ATP III, P=0.001; IDF, P<0.001; WHO, P=0.029). The multiple re-
gression analysis between intima-media thickness (IMT) and clinical values showed that basal C-peptide significantly correlated 
with IMT (P=0.043), while the analysis between the 10-year coronary heart disease risk by the United Kingdom Prospective Di-
abetes Study risk engine and clinical values showed that basal C-peptide did not correlate with IMT (P=0.226). 
Conclusion:  Basal C-peptide is related to cardiovascular predictors (IMT) of T2DM, suggesting that basal C-peptide does pro-
vide a further indication of cardiovascular disease.
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INTRODUCTION
Diabetic subjects show a remarkable increase in cardiovascular 
complications, including myocardial infarctions and strokes, 
which are responsible for the majority of morbidity and mor-
tality [1]. Many individual biomarkers, such as fibrinogen, C-
reactive protein, uric acid, intima-media thickness (IMT) of 
the carotid artery, Framingham Risk Score (FRS), and the Unit-
ed Kingdom Prospective Diabetes Study (UKPDS) risk engine 
have been used as predictors of cardiovascular disease in dia-
betic patients. However, the predictive values of biomarkers 
have not been thoroughly studied [2].
  Type 2 diabetes mellitus (T2DM) is a heterogeneous group 
of disorders characterized by variable degrees of insulin resis-
tance, impaired insulin secretion, and increased glucose pro-
duction [3]. The increases in cardiovascular morbidity and 
mortality appear to relate to the synergism of degree of insulin 
resistance and hyperglycemia, even pre-diabetes [4]. Insulin 
resistance, as reflected by elevated serum insulin level, is asso-
ciated with an increased risk of cardiovascular complications 
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in individuals with and without DM. Serum C-peptide is not 
as well extracted by the liver and, due to the linearity of its ki-
netics, reflects the true pancreatic secretion of insulin [5,6].
  The currently available information establishes that C-pep-
tide is not as biologically inert as previously believed. Instead, 
C-peptide is emerging as an active peptide hormone with po-
tentially important physiological effects. In recent studies, the 
foregoing considerations have dealt primarily with the macro-
vascular complications of diabetes, with elevated levels of C-
peptide being the main focus [7]. However, this concept re-
mains controversial and few studies have reported the relation-
ship between serum C-peptide and chronic complications of 
diabetes. Therefore, the authors of the present study hypothe-
sized that basal C-peptide levels can be used as a cardiovascu-
lar predictor in T2DM patients. 
  The present study was designed to examine whether the bas-
al C-peptide level correlates with cardiovascular risk in T2DM 
patients via comparison with IMT, the 10-year coronary heart 
disease (CHD) risk by UKPDS engine and the metabolic syn-
drome (MS) components.
METHODS
Study population
From October 2005 to June 2009, data was obtained from 1,097 
patients with DM who were hospitalized due to various rea-
sons in two university hospitals in Chungcheongnam Prov-
ince and Jeju Island, Republic of Korea (Fig. 1).
  Among the 1,097 participants, 630 with serum creatinine 
>1.4 mg/dL, DM foot, any inflammatory and infection diseas-
es (urinary tract infection, upper respiratory infection), hepa-
titis or type 1 DM (basal C-peptide<0.5, elevated serum ke-
tone level, and autoimmune islet antibody positive) were ex-
cluded. In addition, 23 participants with missing data for mark-
ers of the exclusion criteria and 20 participants with missing 
data for the traditional risk factors were excluded. The final 
sample for the analyses was comprised of 467 participants 
with T2DM (mean age, 56.75±14.28 years; M:F=213:254).
Data collection and assays
All subjects underwent a clinical examination. Blood samples 
from patients for all biochemical evaluations were collected 
after an overnight fast. Concentrations of lipids, glucose, blood 
urea nitrogen, creatinine, uric acid, homocysteine, fibrinogen 
and routine chemical markers were measured using the stan-
dard laboratory techniques. 
  Glucose, total cholesterol (TC), triglyceride (TG), high den-
sity lipoprotein (HDL), and low density lipoprotein (LDL) 
cholesterol were measured using enzymatic methods (AU 
5400; Olympus, Melville, NY, USA). Serum C-peptide levels 
were assessed using radioimmunoassay (SR 300; STRATEC, 
Birkenfeld, Germany). The intra-assay coefficient of variation 
(CV) was 1.78% and the inter-assay CV was 9.25%. The two 
institutes had the same models of laboratory instruments with 
the same CV values.
  Waist circumference (at the midpoint between the anterior 
superior iliac crest and the lowest rib) was obtained by trained 
researchers using standard techniques. The body mass index 
(BMI) was calculated as weight in kilograms divided by height 
in meters squared. Blood pressure was recorded in duplicate 
after 5 minutes of rest using random-zero sphygmomanome-
ters.
The 10-year CHD risk according to the UKPDS risk engine 
and IMT of the left carotid artery
The 10-year CHD (non-fatal and fatal CHD) risk was calculat-
1,097 Hospitalized patients with 
DM were enrolled
467 Patients comprised the analyses
(mean age, 56.75±14.28 yr, M:F=213:254)
630 Were excluded
77 Hepatitis, any type
219 Serum creatinine >1.4 mg/dL 
69 DM foot
78 Other infection
18 Anti-GAD or ICA 
13 Basal C-peptide<0.5
113 Two more exclusion causes
43 Missing data
23 Any markers of exclusion criteria
20 Any of the traditional risk factors
Fig. 1.  Enrollment and exclusions. From October 2005 to 
June 2009, data was obtained from 1,097 patients with diabe-
tes mellitus (DM), who were hospitalized in one of two uni-
versity hospitals in Chungcheongnam Province and Jeju Is-
land, Republic of Korea. Among the 1,097 participants, 630 
with serum creatinine >1.4 mg/dL, DM foot, an inflammatory 
or infectious disease, hepatitis, or type 1 DM were excluded. 
The final sample for the analyses was comprised of 467 partici-
pants.Basal C-peptide as a marker of subclinical atherosclerosis
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ed for each patient using the UKPDS risk engine (version 2.0 
for Windows, University of Oxford, Oxford, UK) with admis-
sion demographics and fasting lipid profiles. The risk predic-
tors used were age, duration of diabetes, gender, atrial fibrilla-
tion, ethnicity, smoking status, glycated hemoglobin (HbA1c), 
systolic blood pressure (SBP), TC, and HDL.
  The IMT of the left carotid artery was measured by an ex-
pert radiologist on the far wall of the distal common carotid 
artery using a 12 MHz linear probe. Carotid ultrasound, fol-
lowed by a duplex color Doppler examination, was performed 
with a GE LogiQ9 (GE Healthcare, Milwaukee, WI, USA) and 
a linear probe of 7.5 to 12 MHz while the patient was in a su-
pine position. Both left and right common carotid arteries were 
analyzed. Multiple measurements of the distal wall from ante-
rior, lateral, and posterior longitudinal projections were record-
ed. Maximal IMT was measured in two segments of 1 cm each, 
from the flow divider caudally (carotid bulb) and from the be-
ginning of the common carotid bulb (common carotid). The 
IMT value was calculated as an arithmetical mean from the 
bulb and common carotid segments of both sides. The IMT 
measurement was performed in hospitalized patients in Chun-
gcheongnam province.
Definition of MS
Metabolic syndrome was defined according to criteria of the 
Adult Treatment Panel III (ATP III) of the National Cholester-
ol Education Program (NCEP’s), World Health Organization 
(WHO), and the International Diabetes Federation (IDF).
  The WHO criteria [8] for MS required the presence of DM 
or impaired fasting plasma glucose (FPG ≥110 mg/dL) and at 
least two of the following components: 1) diagnosed with hy-
pertension or blood pressure ≥140/90 mm Hg; 2) dyslipid-
emia: TG ≥150 mg/dL or HDL ≤40 mg/dL (male), ≤50 mg/
dL (female); 3) central obesity: waist-hip ratio >0.90 (male); 
>0.85 (female), or BMI ≥30 kg/m
2; or 4) microalbuminuria:
urinary albumin to creatinine ratio ≥30 mg/g. The modified 
ATP III definition of MS [9] required the presence of at least 
three or more of the following five components: 1) elevated 
waist circumference ≥90 cm (male), ≥80 cm (female); 2) ele-
vated TG >150 mg/dL (1.695 mmol/L); 3) reduced HDL<40 
mg/dL (male),<50 mg/dL (female); 4) hypertension or elevat-
ed blood pressure ≥130/85 mm Hg; or 5) diabetes or elevated 
FPG ≥5.6 mmol/L. The 2006 IDF definition classified a per-
son with MS in the same way as did ATP III but required the 
presence of central adiposity (elevated waist circumference) as 
an essential component [10].
Statistical analysis
A statistical analysis was performed with the PASW statistics, 
version 18.0 for Windows (SPSS Inc., Chicago, IL, USA). The 
differences between continuous variables between groups were 
compared using ANOVA and the independent t-test. Pearson’s 
product-moment correlation was used for analysis between 
the basal C-peptide level and MS components. Multiple regres-
sion analysis was used for analysis of the relationship among 
the IMT, 10-year CHD risk by the UKPDS risk engine, and 
clinical variables. Differences were considered statistically sig-
nificant when P<0.05.
RESULTS
General and biochemical characteristics
General and biochemical characteristics of the 467 study sub-
jects (213 men, 254 women) are presented in Table 1. The mean 
age of the subjects was 56.75±14.28 years, and the age range 
was 16-92 years. A total of 413 (67%) subjects from the base 
population of 467 were identified as having MS. The 10-year 
CHD risk according to the UKPDS risk engine was 18.36± 
1.51%, and IMT of the left carotid artery was 0.82±0.34 mm.
  The mean patient BMI was 24.47±4.17 kg/m
2, and over-
weight but not obese subjects were also included. The mean 
DM duration was 8.22±7.63 years, and the mean value was 
9.88±2.67%.
Clinical characteristics of T2DM patients according to 
C-peptide tertile
Basal C-peptide measured on an empty stomach was 2.27± 
1.51 ng/mL. Several clinical parameters were significantly dif-
ferent across the C-peptide tertiles, including BMI, waist cir-
cumference, DM duration, and levels of HbA1c, TG, HDL, 
and uric acid. However, the 10-year CHD risk according to the 
UKPDS and IMT of the left carotid artery were not significant-
ly different by group (Table 1).
Correlations between basal C-peptide level and 
cardiovascular biomarkers
To date, there is no confirmed method to predict specific car-
diovascular events. Accordingly, several markers of inflamma-
tion have been used as predictors of cardiovascular disease, re-
sulting in dependence on indirect estimations such as choles-Kim S-T, et al.
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terol level, blood pressure, and waist circumference. Recently, 
IMT and the UKPDS risk engine have been the focus of many 
studies; therefore, the authors of the present study attempted 
to draw a comparison between cardiovascular risk and above-
mentioned components.
  Correlations were found between basal C-peptide level and 
the clinical components. Simple positive correlations were 
found with FPG, waist circumference, TG, and homocysteine, 
and simple negative correlations were observed for HDL, DM 
duration, and HbA1c. All values were statistically significant 
except for TC, LDL, and SBP, known predictors of cardiovas-
cular disease (TC, P=0.892; LDL, P=0.721; SBP, P=0.183). IMT 
is known as a good correlation of macrovascular complica-
tions and also for having a positive correlation with C-peptide 
(P=0.014) (Table 2). 
Basal C-peptide level according to the presence of MS 
under three different definitions 
Previous results suggested that C-peptide was more correlated 
with MS components such as fasting glucose, TG, waist circum-
ference, and HDL than it was with SBP, TC, and LDL. Hence, 
the authors determined whether the basal C-peptide level had 
statistically significant relationships with the three MS criteria 
(NCEP-ATP III, IDF, WHO) using the independent t-test. Bas-
Table 1.  Clinical characteristics of T2DM patients according to C-peptide tertile 
Characteristic
C-peptide tertile, ng/mL
Total P value
≤1.4 >1.4 - ≤2.6 >2.6
No. 154 163 150 467
Age, yr 56.1±14.7 55.6±13.9 58.6±14.1 56.75±14.28 0.139
Sex (female), % 56.0±0.49 53.0±0.50 54.0±0.50 54.43 0.092
BMI, kg/m
2 23.01±3.80 24.68±4.03 25.78±4.27 24.47±4.17 <0.001
c
Waist circumference, cm 84.31±11.81 88.50±10.12 91.06±10.22 87.95±11.05 <0.001
c
DM duration, yr 9.72±8.26 8.70±7.74 6.64±6.52 8.22±7.63 0.002
c
Smoking
a, % 26.0±4.4 22.0±4.2 31.0±4.6 26.0±4.4 0.213
HbA1c, % 10.71±3.14 10.08±2.18 8.85±2.32 9.88±2.67 <0.001
c
FBS,  mg/dL 160.37±77.49 171.17±71.77 172.66±70.30 168.06±73.23 0.555
SBP, mm Hg  128.45±15.90 125.86±15.50 128.69±15.22 127.62±15.56 0.199
DBP, mm Hg 78.31±9.68 77.87±8.91 79.68±9.26 78.59±9.28 0.206
TC, mg/dL 181.57±46.17 185.53±60.17 185.91±50.96 184.35±52.87 0.733
TG, mg/dL 131.55±114.54 190.08±137.67 204.26±167.85 175.43±144.53 <0.001
c
HDL-C, mg/dL 48.75±14.96 43.85±13.26 44.34±13.04 45.62±13.92 0.003
c
LDL-C, mg/dL 109.77±33.65 116.46±40.51 117.07±36.91 114.46±37.27 0.171
Homocysteine, μmol/L 10.61±3.64 10.63±3.82 11.55±3.65 10.92±3.72 0.057
Uric acid, mg/dL 3.87±1.28 4.16±1.40 4.65±1.61 4.22±1.46 <0.001
c
Fibrinogen, mg/dL 3.11±0.97 3.15±0.79 3.39±1.12 3.22±0.98 0.097
Basal C-peptide, ng/mL 0.98±0.32 1.97±0.33 3.96±1.48 2.27±1.51 <0.001
c
10-yr CHD risk according to  
  the UKPDS risk engine
b, %
18.33±1.56 18.31±1.56 18.46±1.43 18.36±1.51 0.996
IMT of left carotid artery, mm 0.78±0.20 0.75±0.20 0.87±0.43 0.82±0.34 0.217
Values are presented as mean±standard deviation or number (%).
P value was analyzed using ANOVA. 
T2DM, type 2 diabetes mellitus; BMI, body mass index; HbA1c, glycated hemoglobin; FBS, fasting blood sugar; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipopro-
tein cholesterol; CHD, coronary heart disease; UKPDS, United Kingdom Prospective Diabetes Study; IMT, intima-media thickness.
aThis value means the percentage of ex- and current-smokers, 
bValues were non-fatal and fatal CHD risk calculated according to the UKPDS 
risk engine, 
cP values<0.05.Basal C-peptide as a marker of subclinical atherosclerosis
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al C-peptide levels tended to increase according to the presence 
of MS (NCEP-ATP III, P=0.001; IDF, P<0.001; WHO, P=
0.029) (Table 3).
The trend of basal C-peptide level according to the number 
of metabolic components 
Basal C-peptide level increased with the number of metabolic 
components according to the NCEP-ATP III criteria, and the 
increments were statistically significant (P<0.001) (Fig. 2).
Multiple regression analysis with IMT and the 10-year 
CHD risk according to the UKPDS risk engine using 
clinical variables 
The factors which influence the IMT and FRS and which are 
known to be established predictors of macrovascluar compli-
Table 3.  Basal C-peptide levels according to the presence of 
metabolic syndrome under three different criteria  
Basal C-peptide, ng/mL
MetS (+)  MetS (-) P value
a
NCEP-ATP III  2.468±1.57 1.93±1.25 0.001
b
IDF 2.57±1.66 2.04±1.30 < 0.001
b
WHO 2.42±1.61 2.04±1.22 0.029
b
Values are presented as mean±standard deviation.
NCEP, National Cholesterol Education Program; ATP III, Adult 
Treatment Panel III; IDF, International Diabetes Federation; WHO, 
World Health Organization.
aP between subjects with and without metabolic syndrome using in-
dependent t-test, 
bP values<0.05.
Fig. 2.  The trend of basal C-peptide 
level according to number of meta-
bolic components. Basal C-peptide 
level increased according to the num-
ber of metabolic components (P val-
ue<0.001). Metabolic components 
were determined according to NCEP-
ATP III criteria. Values are presented 
as mean±standard deviation.
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Table 2.  Correlations between basal C-peptide level and car-
diovascular biomarkers
Basal C-peptide, ng/mL
r
a P value
FBS, mg/dL 0.141 0.045
b
Waist circumference, cm 0.256 < 0.001
b
TG, mg/dL 0.213 < 0.001
b
HDL, mg/dL -0.107 0.022
b
TC, mg/dL 0.006 0.892
LDL, mg/dL  0.017 0.721
SBP, mm Hg 0.062 0.183
DM duration, yr -0.113 0.030
b
HbA1c, %  -0.277 < 0.001
b
Homocysteine, μmol/L 0.121 0.013
b
Uric acid, mg/dL 0.289 < 0.001
b
10-yr CHD risk according to the 
UKPDS risk engine, %
0.013 0.440
IMT of left carotid, mm 0.231 0.014
b
FBS, fasting blood sugar; TG, triglyceride; HDL, high density lipo-
protein; TC, total cholesterol; LDL, low density lipoprotein; SBP, sys-
tolic blood pressure; DM, diabetes mellitus; CHD, coronary heart 
disease; UKPDS, United Kingdom Prospective Diabetes Study; IMT, 
intima-media thickness.
aPearson’s product-moment correlation coefficient, 
bP values<0.05.Kim S-T, et al.
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cations were investigated.
  The multiple regression analysis between IMT and the clini-
cal values showed that basal C-peptide level had an indepen-
dent positive correlation (b=0.234) with IMT that was statisti-
cally significant (P=0.043). The basal C-peptide level did not 
correlate with the 10-year CHD risk according to the UKPDS 
risk engine (P=0.226) (Table 4). 
DISCUSSION
C-peptide, formed during cleavage of insulin from proinsulin, 
is a by-product of insulin biosynthesis. After the discovery of 
the mode of insulin biosynthesis, several early studies addressed 
the question of possible physiological effects of C-peptide. How-
ever, because C-peptide has not been hormonally demonstrat-
ed, this proinsulin-connecting peptide has been regarded as a 
biologically inert by-product [11]. Recently, the G protein-
coupled receptor with subsequent activation of the Ca
2+-de-
pendent intracellular signaling pathways and the specific bind-
ing of the C-peptide to human cell membranes have been dem-
onstrated [12]. C-peptide effects have been suggested to act 
upon biologically active peptides [13]. According to recent 
studies, C-peptide induces smooth muscle cell (SMC) prolif-
eration, immune response, cell growth and may play a pivotal 
role in the regulation of endothelial function. Previous studies 
have suggested that such mechanisms could facilitate cardio-
vascular events [14,15]. Until now, there have been few studies 
regarding C-peptide and diabetes complications. The authors 
of the present study aimed to determine whether the basal C-
peptide levels were related to cardiovascular risk in T2DM pa-
tients.
  The present study was designed to evaluate the correlations 
between C-peptide levels and clinical values of known cardio-
vascular risk factors such as uric acid, homocystein, SBP, TC, 
LDL-C, TG, HDL-C, waist circumference, CHD risk accord-
ing to the UKPDS risk engine and IMT. In Table 2, C-peptide 
had simple correlations with uric acid, homocystein, TG, HDL-
C, and waist circumference, all of which are components of 
MS. However, the C-peptide level did not significantly corre-
late with TC, LDL-C, or SBP. Cho et al. [16] showed very simi-
lar results. Significant differences were observed in fasting se-
rum C-peptide levels between the abdominal obesity group 
and the other groups of T2DM patients (diagnosed for over 10 
years) (1.80±1.87 μg/L vs. 1.45±1.02 μg/L). Furthermore, C-
peptide was also correlated with fibrinogen, TG, HDL-C, and 
waist circumference.
  Basal C-peptide level has a strong association with insulin 
resistance. Thus, the direct correlations between C-peptide and 
three different MS definitions (NCEP-ATP III, WHO, IDF) 
were verified. In Table 3 and Fig. 2, the basal C-peptide level 
was increased significantly in the MS group with diabetes. Fast-
ing insulin levels are a crude index of insulin secretion and in-
sulin resistance and may underestimate the magnitudes of the 
associations between insulin resistance and components of 
MS [17]. C-peptide appeared to correlate better to the well-
known variables of MS than it did to insulin, possibly suggest-
ing that C-peptide is a better surrogate than insulin for esti-
mating insulin resistance in epidemiological studies [18].
  According to the results from the Multiple Risk Factor In-
tervention Trial (MRFIT) [19], the Veteran Affairs High Den-
sity Lipoprotein Intervention Trial (VA-HIT) [20] and the In-
sulin Resistance Atherosclerosis Study (IRAS) [21], hyperin-
sulinemia and insulin resistance are supported by showing a 
direct relationship between insulin level and cardiovascular 
risk [22]. However, the molecular mechanisms underlying the 
association between insulin resistance and atherosclerosis are 
Table 4.  Multiple regression analysis with IMT and the 10-
year CHD risk according to the UKPDS risk engine with re-
spect to clinical variables
IMT 10-yr CHD risk
β
a P value β
a P value
Age, yr 0.346 0.002
b 0.649 < 0.001
b
Waist circumference, cm -0.020 0.858 -0.052 0.427
SBP, mm Hg 0.116 0.245 0.155 0.011
b
TC, mg/dL 0.395 0.213 0.297 0.039
b
HDL, mg/dL -0.2316 0.085 -0.533 < 0.001
b
LDL-C, mg/dL -0.343 0.202 0.000 0.998
Homocysteine, μmol/L -0.126 0.228 0.155 0.011
b
Uric acid, mg/dL -0.085 0.405 0.008 0.897
Basal C-peptide, ng/mL 0.234 0.043
b -0.080 0.226
FBS, mg/dL -0.149 0.365 0.020 0.755
HbA1c, % 0.029 0.856 0.448 < 0.001
b
DM duration, yr -0.161 0.312 -0.093 0.139
IMT, intima-media thickness; CHD, coronary heart disease; UKPDS, 
United Kingdom Prospective Diabetes Study; SBP, systolic blood 
pressure; TC, total cholesterol; HDL, high density lipoprotein; LDL-
C, low density lipoprotein cholesterol; FBS, fasting blood sugar; DM, 
diabetes mellitus.
aRegression coefficient, 
bP values<0.05.Basal C-peptide as a marker of subclinical atherosclerosis
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still unclear. Hyperglycemia, advanced glycation end products, 
and dyslipidemia also have been suggested to create vascular 
events. Although hyperglycemia has been demonstrated to 
stimulate SMC proliferation in vitro and is thought to contrib-
ute to neointima formation, recent reports challenge the con-
cept by demonstrating no mitogenic activity in high glucose 
environments. Park et al. [23] showed that hyperglycemia in 
streptozotocin-induced diabetic rats was not associated with 
increased neointima formation.
  The Diabetes Control and Complications Trial (DCCT) [24] 
and the UKPDS [25] have provided consistent evidence that 
intensive glycemic control prevents the development and pro-
gression of microvascular complications in patients with types 
1 or 2 diabetes. However, whether intensive glucose reduction 
also prevents macrovascular disease and major cardiovascular 
events remains unclear. Therefore, hyperglycemia is not 
thought to be the main mechanism of cardiovascular compli-
cations in T2DM. 
  Marx and colleagues [26] demonstrated co-localization of 
C-peptide with SMC in early human atherosclerotic lesions of 
diabetic subjects. In vitro stimulation of SMC with C-peptide 
via insulin resistance and compensatory hyperinsulinemia re-
sulted in a dose-dependent induction of smooth cell prolifera-
tion. The study outlined a previously unrecognized role for C-
peptide to act as mitogen for SMC. Wang et al. [27] proposed 
that the presence of metabolic insulin resistance (i.e., dimin-
ished strength of the PI 3-kinase signaling) and the resulting 
compensatory hyperinsulinemia cause SMC proliferation, 
which results in a selective impairment of the PI 3-kinase path-
way with intact signaling along the ERK1/2-MAPK pathway, 
rather than a role in conveying the metabolic action. Current-
ly, insulin acts as a weak mitogen which is not sufficient to in-
fluence the proliferation effect. In other words, C-peptide, in 
conditions which lead to insulin resistance, increases compen-
satory pathways as well as induces several other signaling path-
ways including the ERK1/2-MAPK and PI 3-kinase pathways 
through Src kinase. C-peptide may also have proathergenic ef-
fects, such as stimulation of monocytes and T-cell chemotaxis, 
in atherosclerotic lesions from diabetic patients [28].
  IMT is a good marker of early atherosclerotic changes and 
its progression. IMT is increased in groups of patients with 
several cardiovascular risk factors [29]. The authors of the pres-
ent study attempted to determine the independent factors of 
commonly used methods and markers. In Table 4, C-peptide 
is an independent factor for IMT but not for the 10-year CHD 
risk according to the UKPDS risk engine. 
  The 10-year CHD risk according to the UKPDS risk engine 
was calculated for each patient based on smoking status, total 
serum cholesterol, age, serum LDL-C, and SBP. In the present 
study, Table 2 also shows that basal C-peptide was not associ-
ated with the UKPDS risk engine-related factors. Basal C-pep-
tide was not considered to be an independent factor that influ-
ences the 10-year CHD risk. However, IMT can be directly as-
sessed based on arterial vessel wall changes and SMC prolifer-
ation. As mentioned above, insulin resistance and C-peptide 
are associated with SMC proliferation. Thus, C-peptide was 
thought to be an independent factor for IMT, as shown in Ta-
ble 4. In the Atherosclerosis Risk in the Communities (ARIC) 
study [30], higher levels of endogenous insulin were signifi-
cantly associated with increased thickness of the carotid artery 
wall.
  The Wisconsin Epidemiologic Study of Diabetic Retinopa-
thy (WESDR) [31] is an ongoing prospective, population-based 
cohort study analyzing the relationships of exogenous insulin 
and C-peptide level with ischemic heart disease mortality over 
a 16-year period. In the WESDR study, higher levels of plasma 
C-peptide were also associated with increased risks of death.
  The present study has several limitations. First, the study 
was based on a cross-sectional design, thus the nature of the 
investigation and the results do not imply a general case, and 
longitudinal studies are needed. Second, most of the subjects 
had uncontrolled blood sugar, which may be a risk factor of 
cardiovascular disease. Third, a correlation between insulin 
resistance and C-peptide was not considered when using 
HOMA-IR in the present study. Fourth, basal C-peptide level 
may have been influenced by various medications because the 
study population consisted of newly diagnosed, treated or un-
treated diabetes patients.
  In conclusion, the present study suggests that basal C-pep-
tide level in T2DM is related to MS in that it may be a surro-
gate marker of subclinical atherosclerosis. Further large pro-
spective studies are needed to examine the hypothesis of C-
peptide’s proatherogenic effects. Moreover, additional work is 
necessary to identify the C-peptide receptor.
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